Last updated: 15 April 2021 at 5:24pm EST

Venture Partners Ix, Llcarc... Net Worth

Insiders trading at Karuna Therapeutics Inc

Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over 496,938,545$ worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth 53,814,390$ . The most active insiders traders include Health Llc Pure TechJames HealyRobert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of 18,341,187$. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth 636,600$.



What does Karuna Therapeutics Inc do?

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip



What does Karuna Therapeutics Inc's logo look like?

Karuna Therapeutics Inc logo

Karuna Therapeutics Inc executives and stock owners

Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: